Federated Hermes Inc. Has $71.30 Million Position in Repligen Co. (NASDAQ:RGEN)

Federated Hermes Inc. lessened its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 11.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 396,568 shares of the biotechnology company’s stock after selling 49,325 shares during the period. Federated Hermes Inc.’s holdings in Repligen were worth $71,303,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in RGEN. Parnassus Investments LLC bought a new stake in shares of Repligen during the third quarter worth $87,475,000. Norges Bank bought a new position in Repligen in the fourth quarter valued at about $76,155,000. Alliancebernstein L.P. boosted its holdings in Repligen by 32.9% in the fourth quarter. Alliancebernstein L.P. now owns 1,079,105 shares of the biotechnology company’s stock valued at $182,703,000 after acquiring an additional 267,436 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in Repligen in the third quarter valued at about $41,540,000. Finally, Riverbridge Partners LLC boosted its holdings in Repligen by 94.5% in the third quarter. Riverbridge Partners LLC now owns 417,756 shares of the biotechnology company’s stock valued at $66,427,000 after acquiring an additional 202,960 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Stifel Nicolaus raised their price target on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. KeyCorp raised their price target on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $196.70.

Repligen Price Performance

Shares of RGEN opened at $157.06 on Friday. The company has a current ratio of 7.02, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26. Repligen Co. has a 1 year low of $110.45 and a 1 year high of $211.13. The stock has a market cap of $8.77 billion, a P/E ratio of 218.14, a price-to-earnings-growth ratio of 5.27 and a beta of 1.02. The stock’s 50-day moving average price is $189.09 and its two-hundred day moving average price is $173.09.

Repligen (NASDAQ:RGEN) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.33. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The firm had revenue of $155.74 million for the quarter, compared to analysts’ expectations of $155.38 million. During the same quarter last year, the business earned $0.68 earnings per share. The company’s revenue was down 16.6% compared to the same quarter last year. On average, equities analysts predict that Repligen Co. will post 1.46 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Karen A. Dawes sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total transaction of $193,350.00. Following the sale, the director now owns 87,367 shares of the company’s stock, valued at $16,892,409.45. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director Karen A. Dawes sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total transaction of $193,350.00. Following the sale, the director now owns 87,367 shares of the company’s stock, valued at $16,892,409.45. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Ralf Kuriyel sold 3,517 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the sale, the vice president now directly owns 24,260 shares in the company, valued at approximately $4,699,889.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 25,597 shares of company stock worth $5,039,532. Insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.